Growth hormone-releasing hormone (GHRH), also known as somatoliberin, has emerged as a significant focus in medical research due to its extensive biological activities and therapeutic potential. GHRH, a family of hypothalamic peptide hormones, plays a crucial role in stimulating and modulating the
The development of synthetic intramembrane proteolysis receptors (SNIPRs) engineered by researchers in the United States could be a game-changer for CAR T-cell cancer therapies. This groundbreaking advancement introduces a novel methodology to enhance the precision and safety of CAR T-cell
Triple-negative breast cancer (TNBC) is known for its aggressive nature and limited treatment options. However, a recent breakthrough in personalized immunotherapy offers new hope for patients. Researchers have developed a neoantigen DNA vaccine platform that has shown promising results in
The U.S. Department of Energy's Argonne National Laboratory has been awarded two substantial grants totaling up to $21.7 million from the Advanced Research Projects Agency for Health (ARPA-H), a branch of the Department of Health and Human Services. These significant funds are poised to leverage
The discovery of a critical mechanism involving the protein USP39 has opened new avenues for understanding and potentially treating diseases like retinitis pigmentosa and certain cancers. Researchers have revealed that USP39 plays a crucial role in maintaining the stability of spliceosome subunits
In a significant move for the oncology field, ARTBIO, Inc. has entered into a groundbreaking partnership with 3B Pharmaceuticals GmbH that aims to advance a novel alpha radioligand therapy for treating solid tumors. ARTBIO, known for its innovative AlphaDirect™ platform, focuses on 212Pb-based
